Moreover, combined treatment of intratumoral IL-15 complexes with anti-PD-1mAb led to tumor regression and complete clearance of the EO771 tumor in 83% of mice (ten out of twelve) (Figure 1F and Supplemental Figure S1J), which is above the average overall response rate observed in non-breast solid tumors of patients treated with anti-PD-1mAb alone (~20%) [15]. The gene discussed is IL15; the disease is neoplasm.